The Ensign Group lost over $500 million in market value after Hunterbrook Media and Muddy Waters Research published reports alleging inadequate patient care and data manipulation. At least three law firms have opened securities fraud investigations into the company.
The Ensign Group Inc. shares have lost more than $500 million in market value after two activist research reports in four days accused the skilled nursing provider of delivering inadequate patient care and gaming quality-of-care data.
"Ensign's business model relies on delivering inadequate care to patients while gaming data on quality," Hunterbrook Media wrote in a June 8 report titled "Ensign: The Nursing Home Empire Built On Fatal Neglect." The report, based on a five-month investigation, alleged that former employees in multiple states described systematic misrepresentations of care quality.
The stock fell 8.15 percent, or $13.88, to close at $156.42 on June 8 after the Hunterbrook report. Three days later, Muddy Waters Research published its own findings, sending shares down another 3 percent. The combined decline erased more than $500 million in market capitalization from the June 7 close. Muddy Waters alleged that Ensign operates roughly 20 percent of its facilities by renting licenses from absent administrators, a practice the firm said could amount to fraud against states, Medicare and Medicaid, with potential sanctions in the billions of dollars under the False Claims Act.
At least three law firms — Hagens Berman, Robbins Geller Rudman & Dowd and Kaplan Fox & Kilsheimer — have opened investigations into whether Ensign violated federal securities laws by misleading investors about its compliance and patient care practices. Ensign, which operates 396 healthcare facilities across 17 states, has not publicly responded to the specific allegations. The company on June 16 announced a $60 million increase to its stock buyback program, raising total authorization to $100 million, a move Chief Executive Barry Port said "underscores our confidence in the strength, integrity and upside potential of our company." RBC Capital maintained an Outperform rating and $222 price target on the stock following the reports.
The selloff puts Ensign shares near their lowest level since before the reports, testing investor confidence in a company that had repeatedly assured shareholders that compliance and quality outcomes are precursors to outstanding financial performance. The next catalyst for the stock will be any regulatory action by the Centers for Medicare and Medicaid Services or the Department of Justice, as well as Ensign's quarterly earnings report, which will show whether the allegations have affected facility occupancy and reimbursement rates.
This article is for informational purposes only and does not constitute investment advice.
